Private Advisor Group’s Royalty Pharma RPRX Stock Holding History

Private Advisor Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$515K	Sell	9,179 -1,072	-10%	-$55.8K	﹤0.01%	1778
2026 Q1	$492K	Buy	10,251 +42	+0.4%	+$1.84K	﹤0.01%	1865
2025 Q4	$394K	Buy	10,209 +3,080	+43%	+$117K	﹤0.01%	1976
2025 Q3	$252K	Buy	+7,129	New	+$258K	﹤0.01%	2193
2020 Q3	–	Sell	-550	Closed	-$27K	–	3052
2020 Q2	$27K	Buy	+550	New	+$27.2K	﹤0.01%	2416

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Advisor Group's RPRX Position: Q2 2026 in Review

Private Advisor Group reduced its Royalty Pharma (RPRX) stake by 10% in Q2 2026, selling an estimated $55.8K and leaving 9,179 shares worth $515K. The position accounts for ﹤0.01% of the portfolio, ranked #1778.

Private Advisor Group first reported a position in RPRX in Q2 2020 and has held it in 5 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Private Advisor Group held 9,179 shares of Royalty Pharma worth $515K as of Q2 2026.
Private Advisor Group sold 1,072 Royalty Pharma shares in Q2 2026, an estimated $55.8K.
Royalty Pharma made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #1778 holding.
Private Advisor Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 5 quarters since.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.